Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

615 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rivaroxaban versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism in Patients at Lower Risk of Bleeding.
Caroti KS, Becattini C, Carrier M, Cohen AT, Ekbom A, Khorana AA, Lee AYY, Brescia C, Abdelgawwad K, Psaroudakis G, Rivera M, Schaefer B, Brobert G, Coleman CI. Caroti KS, et al. Among authors: ekbom a. TH Open. 2023 Jul 10;7(3):e206-e216. doi: 10.1055/s-0043-1770783. eCollection 2023 Jul. TH Open. 2023. PMID: 37435565 Free PMC article.
Effectiveness and Safety of Rivaroxaban and Low Molecular Weight Heparin in Cancer-Associated Venous Thromboembolism.
Coleman CI, Caroti KS, Abdelgawwad K, Psaroudakis G, Fatoba S, Rivera M, Schaefer B, Brobert G, Khorana AA, Becattini C, Lee AYY, Ekbom A, Carrier M, Brescia C, Cohen AT. Coleman CI, et al. Among authors: ekbom a. JACC CardioOncol. 2023 Feb 7;5(2):189-200. doi: 10.1016/j.jaccao.2022.10.014. eCollection 2023 Apr. JACC CardioOncol. 2023. PMID: 37144109 Free PMC article.
Rivaroxaban Versus Low-Molecular-Weight Heparins in a Broad Cohort of Patients With Cancer-Associated Venous Thromboembolism: An Analysis of the OSCAR-US Program.
Caroti KS, Khorana AA, Becattini C, Lee AYY, Ekbom A, Carrier M, Cohen AT, Brescia C, Abdelgawwad K, Psaroudakis G, Rivera M, Schaefer B, Brobert G, Coleman CI. Caroti KS, et al. Among authors: ekbom a. Clin Appl Thromb Hemost. 2023 Jan-Dec;29:10760296231189282. doi: 10.1177/10760296231189282. Clin Appl Thromb Hemost. 2023. PMID: 37583314 Free PMC article.
Comparison of Clinical Outcomes in Patients with Active Cancer Receiving Rivaroxaban or Low-Molecular-Weight Heparin: The OSCAR-UK Study.
Cohen AT, Wallenhorst C, Rivera M, Ay C, Schaefer B, Abdelgawwad K, Psaroudakis G, Brobert G, Ekbom A, Lee AYY, Khorana AA, Becattini C, Carrier M, Coleman CI, Martinez C. Cohen AT, et al. Among authors: ekbom a. Thromb Haemost. 2024 Apr 8. doi: 10.1055/a-2259-0662. Online ahead of print. Thromb Haemost. 2024. PMID: 38301711 Free article.
Comparison of rivaroxaban and low molecular weight heparin in the treatment of cancer-associated venous thromboembolism: a Swedish national population-based register study.
Linder M, Ekbom A, Brobert G, Vogtländer K, Balabanova Y, Becattini C, Carrier M, Cohen AT, Coleman CI, Khorana AA, Lee AYY, Psaroudakis G, Abdelgawwad K, Rivera M, Schaefer B, Giunta DH. Linder M, et al. Among authors: ekbom a. J Thromb Thrombolysis. 2024 May 12. doi: 10.1007/s11239-024-02992-1. Online ahead of print. J Thromb Thrombolysis. 2024. PMID: 38735015
Associations between pregnancy-related factors and birth characteristics with risk of rare uterine cancer subtypes: a Nordic population-based case-control study.
Abril J, Trabert B, Troisi R, Grotmol T, Ekbom A, Engeland A, Gissler M, Glimelius I, Madanat-Harjuoja L, Gulbech Ording A, Sørensen HT, Tretli S, Bjørge T. Abril J, et al. Among authors: ekbom a. Cancer Causes Control. 2024 May;35(5):741-747. doi: 10.1007/s10552-023-01832-6. Epub 2023 Dec 22. Cancer Causes Control. 2024. PMID: 38129544
615 results